Understanding GLP-1 Receptor Agonists and Their Growing Role

Glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 receptor agonists or GLP-1 RAs, are a class of medications originally developed to manage type 2 diabetes by mimicking the GLP-1 hormone produced in the intestines. This hormone plays a key role in regulating blood sugar levels by stimulating insulin release, slowing gastric emptying, and reducing appetite signals to the brain. Popular examples include semaglutide, marketed as Ozempic for diabetes and Wegovy for weight management, as well as liraglutide (Victoza, Saxenda) and tirzepatide (Mounjaro, Zepbound), which acts on both GLP-1 and another hormone called GIP.

These drugs have revolutionized treatment for obesity and diabetes, with millions using them worldwide due to their effectiveness in promoting significant weight loss—often 15-20% of body weight—and improving metabolic health. Administered via weekly injections, they work by activating GLP-1 receptors not only in the gut and pancreas but also in the brain, influencing areas that control hunger, reward, and motivation. Recent research has uncovered an unexpected benefit: their potential to influence behaviors related to substance use disorders (SUDs), a category encompassing alcohol use disorder, opioid use disorder, nicotine dependence, cannabis use disorder, and cocaine use disorder, among others.

Substance use disorders affect tens of millions globally, characterized by compulsive use despite harmful consequences, driven by changes in the brain's reward circuitry. Traditional treatments like behavioral therapy, counseling, and medications such as naltrexone for alcohol or buprenorphine for opioids target specific substances but often fall short in addressing polysubstance use or cravings. GLP-1 RAs may offer a novel approach by broadly modulating these neural pathways.

📊 Landmark Large-Scale Study: Reduced SUD Risks in Veterans

A pivotal study published in March 2026 in The BMJ analyzed electronic health records from over 606,000 U.S. veterans with type 2 diabetes, emulating randomized trials by comparing new users of GLP-1 RAs to those starting sodium-glucose cotransporter-2 (SGLT-2) inhibitors, another diabetes drug class not linked to addiction effects. Researchers from Washington University in St. Louis and the VA St. Louis Health Care System followed participants for up to three years, focusing on two groups: those without prior SUD history and those with preexisting SUDs.

For individuals without prior SUDs (over 524,000 participants), GLP-1 RA initiation was associated with a 14% overall lower risk of developing any new SUD (hazard ratio [HR] 0.86), translating to about seven fewer cases per 1,000 people over three years. Specific reductions included:

• Alcohol use disorder: 18% lower risk (HR 0.82, net risk difference [NRD] -5.57 per 1,000)
• Opioid use disorder: 25% lower (HR 0.75, NRD -0.86)
• Cocaine use disorder: 20% lower (HR 0.80, NRD -0.97)
• Cannabis use disorder: 14% lower (HR 0.86, NRD -2.25)
• Nicotine use disorder: 20% lower (HR 0.80, NRD -1.64)

Among the 81,000 veterans with preexisting SUDs, benefits were even more pronounced, with GLP-1 RAs linked to fewer severe outcomes:

These findings held across subgroups by age, sex, race, BMI, and specific GLP-1 drugs like semaglutide. The study adjusted for numerous confounders, including comorbidities and healthcare use, using advanced statistical methods to mimic trial conditions. For full details, read the original BMJ study.

Mechanisms: How GLP-1 RAs Target the Brain's Reward System

GLP-1 receptors are densely expressed in brain regions central to addiction, including the ventral tegmental area (VTA), nucleus accumbens (NAc), and hypothalamus—key nodes in the mesolimbic dopamine pathway. This pathway drives the euphoria from drugs, alcohol, or nicotine by releasing dopamine, reinforcing repeated use.

Unlike gut-localized effects, GLP-1 RAs cross the blood-brain barrier at therapeutic doses, binding receptors to dampen dopamine surges triggered by addictive cues. Preclinical studies in rodents and monkeys show reduced self-administration of cocaine, heroin, alcohol, and nicotine; for instance, semaglutide cut voluntary alcohol intake in vervet monkeys without causing nausea. Human brain imaging reveals decreased activity in reward areas during food or drug cues after GLP-1 treatment.

Additional pathways include enhanced GABA inhibition, serotonin modulation, and stress reduction via hypothalamic-pituitary-adrenal axis regulation, explaining broad effects across substances. This contrasts with substance-specific drugs, positioning GLP-1 RAs as potential "upstream" interveners in addiction vulnerability.

Broader Evidence: From Trials to Real-World Data

Supporting the VA study, a 2025 JAMA Psychiatry trial found weekly semaglutide reduced alcohol craving and consumption in adults with alcohol use disorder over nine weeks. A Swedish cohort of 227,000 linked GLP-1 use to doubled reductions in alcohol-related events versus standard treatments. Observational data show lower opioid overdoses and cannabis relapses with GLP-1 RAs.

Over a dozen clinical trials are underway testing semaglutide and others for alcohol, opioid, and nicotine dependence. Animal models consistently demonstrate attenuated reward and relapse prevention. Anecdotal reports from patients note obliterated cravings for alcohol, cigarettes, and opioids alongside appetite suppression. Explore more in this JAMA Psychiatry trial on semaglutide for AUD.

Professionals researching these intersections can find opportunities in clinical research jobs to advance this field.

Implications for Prevention and Treatment Strategies

This research suggests GLP-1 RAs could prevent SUD onset in at-risk groups, like those with diabetes or obesity—common comorbidities with addiction. For existing SUD patients, they may serve as adjuncts, reducing hospitalizations and deaths, especially amid the opioid crisis claiming over 100,000 U.S. lives yearly.

Actionable steps: Patients on Ozempic for metabolic issues should monitor substance cravings with providers. Those with SUD history might discuss off-label use, weighing benefits against side effects like nausea, gastrointestinal issues, or rare pancreatitis. Broad-spectrum action suits polysubstance users, comprising most cases.

Challenges include access (high costs, shortages), long-term adherence, and rebound risks upon stopping. In higher education, this spurs interdisciplinary research; faculty in pharmacology or psychiatry can lead trials via research jobs.

Limitations, Caveats, and the Path Forward

As an observational study in a mostly older, male VA population, results may not fully generalize to women, younger adults, or civilians. Residual confounding or underdiagnosis of SUDs is possible, though rigorous adjustments minimized biases. GLP-1 RAs aren't approved for SUDs; prescribing solely for addiction lacks support.

Ongoing randomized controlled trials (RCTs) will clarify causality, optimal dosing, and effects in non-diabetic populations. Long-term data on brain adaptation or motivation side effects are needed. Until then, integrate findings cautiously into care.

Photo by Haberdoedas on Unsplash

Wrapping Up: Hope on the Horizon for Addiction Recovery

The VA study's revelations position GLP-1 drugs like Ozempic as promising tools against substance use disorders, offering prevention and harm reduction across addictions. As research accelerates, they could transform care for millions struggling with alcohol, opioids, and more.

Academics and students exploring health sciences can rate my professor experiences in related courses or browse higher ed jobs in medical research. For career advice, visit higher ed career advice, and check university jobs to contribute to breakthroughs. Share your thoughts in the comments below—what do you think of these findings?